The DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.
Mechanism of Inhibition of Ebola Virus RNA-Dependent RNA Polymerase by Remdesivir
Open accessAbstract
Remdesivir (GS-5734) is a 1′-cyano-substituted adenosine nucleotide analogue prodrug that shows broad-spectrum antiviral activity against several RNA viruses. This compound is currently under clinical development for the treatment of Ebola virus disease (EVD). While antiviral effects have been demonstrated in cell culture and in non-human primates, the mechanism of action of Ebola virus (EBOV) inhibition for remdesivir remains to be fully elucidated. The EBOV RNA-dependent RNA polymerase (RdRp) complex was recently expressed and purified, enabling biochemical studies with the relevant triphosphate (TP) form of remdesivir and its presumptive target. In this study, we confirmed that remdesivir-TP is able to compete for incorporation with adenosine triphosphate (ATP). Enzyme kinetics revealed that EBOV RdRp and respiratory syncytial virus (RSV) RdRp incorporate ATP and remdesivir-TP with similar efficiencies. The selectivity of ATP against remdesivir-TP is ~4 for EBOV RdRp and ~3 for RSV RdRp. In contrast, purified human mitochondrial RNA polymerase (h-mtRNAP) effectively discriminates against remdesivir-TP with a selectivity value of ~500-fold. For EBOV RdRp, the incorporated inhibitor at position i does not affect the ensuing nucleotide incorporation event at position i+1. For RSV RdRp, we measured a ~6-fold inhibition at position i+1 although RNA synthesis was not terminated. Chain termination was in both cases delayed and was seen predominantly at position i+5. This pattern is specific to remdesivir-TP and its 1′-cyano modification. Compounds with modifications at the 2′-position show different patterns of inhibition. While 2′-C-methyl-ATP is not incorporated, ara-ATP acts as a non-obligate chain terminator and prevents nucleotide incorporation at position i+1. Taken together, our biochemical data indicate that the major contribution to EBOV RNA synthesis inhibition by remdesivir can be ascribed to delayed chain termination. The long distance of five residues between the incorporated nucleotide analogue and its inhibitory effect warrant further investigation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
McHutchison, J. G., Gordon, S. C., Schiff, E. R., Shiffman, M. L., Lee, W. M., Rustgi, V. K., Goodman, Z. D., Ling, M.-H., Cort, S., & Albrecht, J. K. (1998) · New England Journal of Medicine · doi:10.1056/nejm199811193392101 · Cited by 3,465
Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys
Warren, T. K., Jordan, R., Lo, M. K., Ray, A. S., Mackman, R. L., Soloveva, V., Siegel, D., Perron, M., Bannister, R., Hui, H. C., et al. (2016) · Nature · doi:10.1038/nature17180 · Cited by 1,556
Self-citationAgostini, M. L., Andres, E. L., Sims, A. C., Graham, R. L., Sheahan, T. P., Lu, X., Smith, E. C., Case, J. B., Feng, J. Y., Jordan, R., et al. (2018) · mBio · doi:10.1128/mbio.00221-18 · Cited by 1,416
Self-citationFavipiravir (T-705), a novel viral RNA polymerase inhibitor
Furuta, Y., Gowen, B. B., Takahashi, K., Shiraki, K., Smee, D. F., & Barnard, D. L. (2013) · Antiviral Research · doi:10.1016/j.antiviral.2013.09.015 · Cited by 1,072
Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase
FURUTA, Y., KOMENO, T., & NAKAMURA, T. (2017) · Proceedings of the Japan Academy, Series B · doi:10.2183/pjab.93.027 · Cited by 1,070
Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp
Qiu, X., Wong, G., Audet, J., Bello, A., Fernando, L., Alimonti, J. B., Fausther-Bovendo, H., Wei, H., Aviles, J., Hiatt, E., et al. (2014) · Nature · doi:10.1038/nature13777 · Cited by 987
Broad-Spectrum Antiviral Activity of Virazole: 1-β-D-Ribofuranosyl-1,2,4-triazole-3-carboxamide
Sidwell, R. W., Huffman, J. H., Khare, L., Allen, B., Witkowski, R., & Robins, K. (1972) · Science · doi:10.1126/science.177.4050.705 · Cited by 985
Henao-Restrepo, A. M., Longini, I. M., Egger, M., Dean, N. E., Edmunds, W. J., Camacho, A., Carroll, M. W., Doumbia, M., Draguez, B., Duraffour, S., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(15)61117-5 · Cited by 793
Siegel, D., Hui, H. C., Doerffler, E., Clarke, M. O., Chun, K., Zhang, L., Neville, S., Carra, E., Lew, W., Ross, B., et al. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b01594 · Cited by 643
Self-citationProtection against filovirus diseases by a novel broad-spectrum nucleoside analogue BCX4430
Warren, T. K., Wells, J., Panchal, R. G., Stuthman, K. S., Garza, N. L., Van Tongeren, S. A., Dong, L., Retterer, C. J., Eaton, B. P., Pegoraro, G., et al. (2014) · Nature · doi:10.1038/nature13027 · Cited by 610
Mechanism of Action of T-705 against Influenza Virus
Furuta, Y., Takahashi, K., Kuno-Maekawa, M., Sangawa, H., Uehara, S., Kozaki, K., Nomura, N., Egawa, H., & Shiraki, K. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.3.981-986.2005 · Cited by 546
A Randomized, Controlled Trial of ZMapp for Ebola Virus Infection
The PREVAIL II Writing Group (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1604330 · Cited by 520
GS-5734 and its parent nucleoside analog inhibit Filo-, Pneumo-, and Paramyxoviruses
Lo, M. K., Jordan, R., Arvey, A., Sudhamsu, J., Shrivastava-Ranjan, P., Hotard, A. L., Flint, M., McMullan, L. K., Siegel, D., Clarke, M. O., et al. (2017) · Scientific Reports · doi:10.1038/srep43395 · Cited by 513
In Vitro and In Vivo Activities of Anti-Influenza Virus Compound T-705
Furuta, Y., Takahashi, K., Fukuda, Y., Kuno, M., Kamiyama, T., Kozaki, K., Nomura, N., Egawa, H., Minami, S., Watanabe, Y., et al. (2002) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.46.4.977-981.2002 · Cited by 501
Baculovirus expression system for heterologous multiprotein complexes
Berger, I., Fitzgerald, D. J., & Richmond, T. J. (2004) · Nature Biotechnology · doi:10.1038/nbt1036 · Cited by 496
Oestereich, L., Lüdtke, A., Wurr, S., Rieger, T., Muñoz-Fontela, C., & Günther, S. (2014) · Antiviral Research · doi:10.1016/j.antiviral.2014.02.014 · Cited by 493
Mühlberger, E., Weik, M., Volchkov, V. E., Klenk, H.-D., & Becker, S. (1999) · Journal of Virology · doi:10.1128/jvi.73.3.2333-2342.1999 · Cited by 486
Sissoko, D., Laouenan, C., Folkesson, E., M’Lebing, A.-B., Beavogui, A.-H., Baize, S., Camara, A.-M., Maes, P., Shepherd, S., Danel, C., et al. (2016) · PLOS Medicine · doi:10.1371/journal.pmed.1001967 · Cited by 478
Witkowski, J. T., Robins, R. K., Sidwell, R. W., & Simon, L. N. (1972) · Journal of Medicinal Chemistry · doi:10.1021/jm00281a014 · Cited by 471
T-705 (favipiravir) and related compounds: Novel broad-spectrum inhibitors of RNA viral infections
Furuta, Y., Takahashi, K., Shiraki, K., Sakamoto, K., Smee, D. F., Barnard, D. L., Gowen, B. B., Julander, J. G., & Morrey, J. D. (2009) · Antiviral Research · doi:10.1016/j.antiviral.2009.02.198 · Cited by 471
Favipiravir as a potential countermeasure against neglected and emerging RNA viruses
Delang, L., Abdelnabi, R., & Neyts, J. (2018) · Antiviral Research · doi:10.1016/j.antiviral.2018.03.003 · Cited by 388
Inhibition of Hepatitis C Virus RNA Replication by 2′-Modified Nucleoside Analogs
Carroll, S. S., Tomassini, J. E., Bosserman, M., Getty, K., Stahlhut, M. W., Eldrup, A. B., Bhat, B., Hall, D., Simcoe, A. L., LaFemina, R., et al. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m210914200 · Cited by 335
The HBV Drug Entecavir — Effects on HIV-1 Replication and Resistance
McMahon, M. A., Jilek, B. L., Brennan, T. P., Shen, L., Zhou, Y., Wind-Rotolo, M., Xing, S., Bhat, S., Hale, B., Hegarty, R., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa067710 · Cited by 292
Identification of BMS-200475 as a potent and selective inhibitor of hepatitis B virus
Innaimo, S. F., Seifer, M., Bisacchi, G. S., Standring, D. N., Zahler, R., & Colonno, R. J. (1997) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.41.7.1444 · Cited by 273
Jin, Z., Smith, L. K., Rajwanshi, V. K., Kim, B., & Deval, J. (2013) · PLoS ONE · doi:10.1371/journal.pone.0068347 · Cited by 268
Smither, S. J., Eastaugh, L. S., Steward, J. A., Nelson, M., Lenk, R. P., & Lever, M. S. (2014) · Antiviral Research · doi:10.1016/j.antiviral.2014.01.012 · Cited by 228
MultiBac: Multigene Baculovirus‐Based Eukaryotic Protein Complex Production
Bieniossek, C., Richmond, T. J., & Berger, I. (2008) · Current Protocols in Protein Science · doi:10.1002/0471140864.ps0520s51 · Cited by 182
Julander, J. G., Siddharthan, V., Evans, J., Taylor, R., Tolbert, K., Apuli, C., Stewart, J., Collins, P., Gebre, M., Neilson, S., et al. (2017) · Antiviral Research · doi:10.1016/j.antiviral.2016.11.003 · Cited by 162
Antibody-mediated protection against Ebola virus
Saphire, E. O., Schendel, S. L., Gunn, B. M., Milligan, J. C., & Alter, G. (2018) · Nature Immunology · doi:10.1038/s41590-018-0233-9 · Cited by 138
Mechanism of Binding to Ebola Virus Glycoprotein by the ZMapp, ZMAb, and MB-003 Cocktail Antibodies
Davidson, E., Bryan, C. F., Fong, R. H., Barnes, T., Pfaff, J. M., Mabila, M. N., Rucker, J. B., & Doranz, B. J. (2015) · Journal of Virology · doi:10.1128/jvi.01490-15 · Cited by 132
Initiation, extension, and termination of RNA synthesis by a paramyxovirus polymerase
Jordan, P. C., Liu, C., Raynaud, P., Lo, M. K., Spiropoulou, C. F., Symons, J. A., Beigelman, L. N., & Deval, J. (2018) · PLoS Pathogens · doi:10.1371/journal.ppat.1006889 · Cited by 129
Antiviral efficacy of favipiravir against Ebola virus: A translational study in cynomolgus macaques
Guedj, J., Piorkowski, G., Jacquot, F., Madelain, V., Nguyen, T. H. T., Rodallec, A., Günther, S., Carbonnelle, C., Mentré, F., Raoul, H., et al. (2018) · PLoS Medicine · doi:10.1371/journal.pmed.1002535 · Cited by 128
Efficacy of favipiravir (T-705) in nonhuman primates infected with Ebola virus or Marburg virus
Bixler, S. L., Bocan, T. M. A., Wells, J., Wetzel, K. S., Tongeren, S. A. V., Dŏng, L., Garza, N. L., Donnelly, G., Cazares, L. H., Nuss, J. E., et al. (2017) · Antiviral Research · doi:10.1016/j.antiviral.2017.12.021 · Cited by 100
The Respiratory Syncytial Virus Polymerase Has Multiple RNA Synthesis Activities at the Promoter
Noton, S. L., Deflubé, L. R., Tremaglio, C. Z., & Fearns, R. (2012) · PLoS Pathogens · doi:10.1371/journal.ppat.1002980 · Cited by 98
Deval, J., Hong, J., Wang, G., Taylor, J., Smith, L. K., Fung, A. D., Stevens, S., Liu, H. D., Jin, Z., Dyatkina, N. B., et al. (2015) · PLoS Pathogens · doi:10.1371/journal.ppat.1004995 · Cited by 97
Ribavirin revisited in the era of direct‐acting antiviral therapy for hepatitis C virus infection
Feld, J. J., Jacobson, I. M., Sulkowski, M., Poordad, F. F., Tatsch, F., & Pawlotsky, J. (2016) · Liver International · doi:10.1111/liv.13212 · Cited by 93
Polymerases of paramyxoviruses and pneumoviruses
Fearns, R., & Plemper, R. K. (2017) · Virus Research · doi:10.1016/j.virusres.2017.01.008 · Cited by 86
Friedrich, M. J. (2014) · JAMA · doi:10.1001/jama.2014.4765 · Cited by 85
Uebelhoer, L. S., Albariño, C. G., McMullan, L. K., Chakrabarti, A. K., Vincent, J. P., Nichol, S. T., & Towner, J. S. (2014) · Antiviral Research · doi:10.1016/j.antiviral.2014.03.018 · Cited by 77
Jin, Z., Tucker, K., Lin, X., Kao, C. C., Shaw, K., Tan, H. T., Symons, J. A., Behera, I., Rajwanshi, V. K., Dyatkina, N. B., et al. (2015) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01391-15 · Cited by 67
Recombinant RNA-Dependent RNA Polymerase Complex of Ebola Virus
Tchesnokov, E. P., Raeisimakiani, P., Ngure, M., Marchant, D., & Götte, M. (2018) · Scientific Reports · doi:10.1038/s41598-018-22328-3 · Cited by 61
Self-citationJin, Z., Kinkade, A., Behera, I., Chaudhuri, S. M., Tucker, K., Dyatkina, N. B., Rajwanshi, V. K., Wang, G., Jekle, A., Smith, D. B., et al. (2017) · Antiviral Research · doi:10.1016/j.antiviral.2017.04.005 · Cited by 49
Smidansky, E. D., Arnold, J. J., Reynolds, S. L., & Cameron, C. E. (2011) · Biochemistry · doi:10.1021/bi200350d · Cited by 27
Kimble, J. B., Malherbe, D. C., Meyer, M., Gunn, B. M., Karim, M. M., Ilinykh, P. A., Iampietro, M., Mohamed, K. S., Negi, S. S., Gilchuk, P., et al. (2018) · Journal of Virology · doi:10.1128/jvi.01845-18 · Cited by 21
Cited by
Guo (2020) · doi:10.1186/s40779-020-00240-0 · Cited by 4,735
Sheahan, T. P., Sims, A. C., Leist, S. R., Schäfer, A., Won, J., Brown, A. J., Montgomery, S. A., Hogg, A., Babusis, D., Clarke, M. O., et al. (2020) · Nature Communications · doi:10.1038/s41467-019-13940-6 · Cited by 1,738
Self-citationStructural basis for inhibition of the RNA-dependent RNA polymerase from SARS-CoV-2 by remdesivir
Yin, W., Mao, C., Luan, X., Shen, D.-D., Shen, Q., Su, H., Wang, X., Zhou, F., Zhao, W., Gao, M., et al. (2020) · Science · doi:10.1126/science.abc1560 · Cited by 1,219
“Thus, Remdesivir, like many nucleotide analog prodrugs, inhibits the viral RdRp activity through non-obli-gate RNA chain termination, a mechanism that requires the conversion of the parent drug to the active triphosphate form ( 27 , 28 ).”
BackgroundSheahan, T. P., Sims, A. C., Zhou, S., Graham, R. L., Pruijssers, A. J., Agostini, M. L., Leist, S. R., Schäfer, A., Dinnon, K. H., Stevens, L. J., et al. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.abb5883 · Cited by 1,071
The epidemiology, diagnosis and treatment of COVID-19
Zhai, P., Ding, Y., Wu, X., Long, J., Zhong, Y., & Li, Y. (2020) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2020.105955 · Cited by 1,014
Metadata
- Authors
- Tchesnokov, E. P., Feng, J. Y., Porter, D. P., & Götte, M.
- Venue
- Viruses
- Publisher
- MDPI AG
- Published
- 2019-04-04
- Volume
- 11
- Issue
- 4
- Pages
- 326
- ISSN
- 1999-4915 (ISSN-L)
- OpenAlex
- W2935101654
- Cited by
- 622
- References
- 44
- FWCI
- 84.94
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.